Today: 29 June 2026
Browse Category

NASDAQ:INTS 30 October 2025 - 31 October 2025

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Intensity Therapeutics shares were flat-to-down during Oct. 2025 until the news, trading around $0.27 on Oct. 29ts2.tech. On Oct. 30, publication of its trial in Lancet sent the stock parabolic: intraday it soared nearly 395%, closing at $1.32benzinga.com. In after-hours trading, the stock gave up much of the gain and traded around $0.90 by the end of Thursdaybenzinga.com. A massive volume surge accompanied the move – hundreds of millions of shares changed handsts2.tech. Despite this spike, INTS remains a micro-cap; even at $1+ per share, market cap is only on the order of $50–$60 millionbenzinga.com. The stock’s 52-week range remains very wide, highlighting its extreme volatility. Analysts note that even after the rally, INTS is still very cheap by biotech standards. Before the news, many price targets far exceeded the stock pricets2.techmarketbeat.com. For context, MarketBeat shows a “Moderate Buy” consensus with an average 12‑month target of ~$4.50marketbeat.com. Some sources even cite targets as high as $8.50. In short-term charts, technical indicators now show INTS as extremely overboughtstockinvest.us, suggesting a pullback or consolidation may occur in the near term.
31 October 2025
··
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Intensity Therapeutics has been one of the market’s biggest movers. On Oct. 30, 2025 its stock was around $0.27 per share investing.com – an 84% drop YTD but up nearly 200% intraday on the news of its Lancet-published trial tipranks.com. Trading volume exploded: ~279 million shares traded on Oct. 30 vs. an average of ~5 M per day tipranks.com. The rally was sparked by the Phase 1/2 study announcement that Intensity’s lead drug, INT230‑6, showed striking tumor control in advanced cancer. The study covered 64 patients across 20+ tumor types – most had failed multiple therapies. Remarkably, 75% of patients experienced disease stabilization or response, and median overall survival was 11.9 months investing.com, far above historical norms. Company President/CEO Lewis Bender hailed the data and noted that Intensity has already launched further trials: “Given the drug’s mechanism of action and the data reported in this paper… we believe the study results show the potential of INT230‑6 to achieve clinical benefit for metastatic patients of multiple cancer types… As a result, we have initiated randomized controlled studies, including a Phase 3 study in sarcoma.” tipranks.com. On Oct. 29, a manuscript in Lancet Discovery Science detailed the INT230‑6 trial outcomes d1io3yog0oux5.cloudfront.net investing.com.
30 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 30.10.2025

ENDEDLive coverage has endedEnded: October 31, 2025, 12:00 AM EDT Liberty Latin America (LILA) Valuation Under Scrutiny as Shares Slide Despite Solid Fundamentals October 30, 2025, 10:36 PM EDT. Liberty Latin America (LILA) has fallen ~6% over the last month despite solid annual revenue growth and a rebound in net income. Its 1-year total shareholder return is down >20%, even after a strong rally earlier this year and a ~21% YTD gain. The stock trades at a discount to analyst targets, with a fair value around $10.63 versus a recent close near $7.77, suggesting an undervalued setup for patient investors.
30 October 2025
·······

Stock Market Today

  • ASX Penny Stocks: Alligator Energy, Hearts and Minds, Hansen Technologies in Focus
    June 29, 2026, 3:56 PM EDT. Penny stocks on the ASX are grabbing attention as volatility continues. Alligator Energy (ASX:AGE) is still pre-revenue, valued at A$230.73 million, and betting on uranium exploration. The company is running deeper losses but says its cash should last 2.7 years, and analysts see a possible 62.8% jump in shares. Hearts and Minds Investments (ASX:HM1) has a market cap of A$670.92 million. The investment firm's profits are down 84.9%, and its 6.48% dividend yield has investors wondering about longevity. Hansen Technologies sits at a A$904.29 million market cap, pulling in revenue from its Energy & Utilities business. Together, the names show the range of plays and issues in the ASX penny stock scene.
Go toTop